Stoke Therapeutics (STOK) Common Equity (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Common Equity of $394.9 million for Q1 2026, up 12.8% year-over-year from $350.1 million in Q1 2025, and up 12.04% quarter-over-quarter from $352.5 million in Q4 2025.
Stoke Therapeutics (STOK) Common Equity (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $394.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 12.8% year-over-year to $394.9 million; the TTM figure through Mar 2026 stood at $394.9 million (up 12.8% YoY), while the FY2025 annual figure was $352.5 million, up 53.9% from the prior year.
- Common Equity for Q1 2026 stood at $394.9 million, up from $352.5 million in the prior quarter.
- The five-year high for Common Equity was $394.9 million in Q1 2026, with the low at $140.3 million in Q1 2024.
- The 5-year median for Common Equity is $229.0 million (2024), against an average of $245.6 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 34.37% in 2024, then soared 149.44% in 2025.
- Stoke Therapeutics' Common Equity stood at $184.8 million in 2022, then fell by 13.68% to $159.6 million in 2023, then jumped by 43.53% to $229.0 million in 2024, then jumped by 53.9% to $352.5 million in 2025, then gained by 12.04% to $394.9 million in 2026.
- Business Quant data shows STOK's Common Equity at $394.9 million in Q1 2026, $352.5 million in Q4 2025, and $308.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 345.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 345.55 Mn |
| Mar 31, 2026 | 394.88 Mn |
| Dec 31, 2025 | 352.46 Mn |
| Sep 30, 2025 | 308.11 Mn |
| Jun 30, 2025 | 334.94 Mn |
| Mar 31, 2025 | 350.07 Mn |
| Dec 31, 2024 | 229.02 Mn |
| Sep 30, 2024 | 232.11 Mn |
| Jun 30, 2024 | 242.71 Mn |
| Mar 31, 2024 | 140.34 Mn |
| Dec 31, 2023 | 159.57 Mn |
| Sep 30, 2023 | 173.00 Mn |
| Jun 30, 2023 | 190.20 Mn |
| Mar 31, 2023 | 213.82 Mn |
| Dec 31, 2022 | 184.85 Mn |
| Sep 30, 2022 | 204.14 Mn |
| Jun 30, 2022 | 224.32 Mn |
| Mar 31, 2022 | 239.98 Mn |
| Dec 31, 2021 | 217.78 Mn |
| Sep 30, 2021 | 237.51 Mn |